New Drug Daraxonrasib Hailed as Major Breakthrough in Pancreatic Cancer Treatment

Experts are excited about a new drug, daraxonrasib, which nearly doubled survival outcomes in a pivotal trial, marking a significant advance in treating pancreatic cancer, one of the most aggressive forms of cancer.

The top 3

  1. Deadliest Cancers: Pancreatic Rank: Pancreatic cancer ranks as the third-leading cause of cancer-related deaths in the U.S. and is projected to become the second by 2030, holding the highest mortality rate among major cancers with a five-year survival rate of just 13%.
  2. Survival Rate: Progress & Stalls: The five-year survival rate for pancreatic cancer has tripled from 1-3% in the late 1970s to 13% today, though this progress has stalled at 13% for the past three years.
  3. Why Pancreatic Cancer is Tough: Pancreatic cancer is notoriously difficult to treat due to late diagnosis, tumors encased in dense scar tissue, its common KRAS gene mutations, and its ability to suppress immune responses.

Sources

Open the full topic